ReNetX focuses on spinal cord injury patients

ReNetX Bio’s NoGo Trap therapeutic has been given “fast track” status by the Food and Drug Administration. The firm’s mission statement is clear and precise: “to boldly advance first-in-class therapeutics for people living with currently incurable neurological disorders.”

The injected therapeutic has shown promise in primates leading to a rare human trial using patients with chronic spinal cord injuries.